Value-Based Pricing of Resmetirom for Metabolic Dysfunction–Associated Steatotic Liver Disease
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2025.17122
Abstract: Key Points Question Compared with standard of care, is resmetirom cost-effective in treating metabolic dysfunction–associated steatohepatitis and significant fibrosis among US adults in a simulated cohort? Findings In this economic evaluation, at a price of… read more here.
Keywords: resmetirom; value based; dysfunction associated; metabolic dysfunction ... See more keywords
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-70242-8
Abstract: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important public health problem owing to its high prevalence and associated morbidity and mortality secondary to progressive liver disease and cardiovascular events. Resmetirom, a selective thyroid hormone… read more here.
Keywords: treatment; meta analysis; resmetirom; safety ... See more keywords
Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Gastroenterology and Hepatology"
DOI: 10.1111/jgh.16874
Abstract: Resmetirom, the first FDA‐approved drug for nonalcoholic steatohepatitis (NASH) with fibrosis in obese patients, when combined with lifestyle modifications, improves NASH resolution and reduces fibrosis by at least one stage. Low thyroid hormone (T3) levels… read more here.
Keywords: thyromimetics masld; novel molecules; masld unveiling; unveiling novel ... See more keywords
Abstract 4140504: Effect Of Resmetirom On Lipid Panel: Meta-Analysis Of Randomized Controlled Trials
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4140504
Abstract: Background: Resmetirom is useful in improving liver parameters in patients with nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH). However, its beneficial effects on lipid panel parameters are unclear. Methods: We searched PubMed and ClinicalTrials.gov… read more here.
Keywords: resmetirom lipid; controlled trials; randomized controlled; resmetirom ... See more keywords
Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Basic and Clinical Physiology and Pharmacology"
DOI: 10.1515/jbcpp-2024-0140
Abstract: Abstract Introduction Metabolic-Associated Steatohepatitis-Related Liver Disease (MASLD) and, its progressive form, Metabolic-Associated Steatohepatitis (MASH) pose significant global health challenges. Current therapeutic strategies targeting metabolic abnormalities have shown promise but lack specificity for the liver. Thyroid… read more here.
Keywords: mash; masld mash; network meta; resmetirom ... See more keywords
Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier
Sign Up to like & getrecommendations! Published in 2025 at "Biomedicines"
DOI: 10.3390/biomedicines13092079
Abstract: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease linked to type 2 diabetes (T2D), obesity, and dyslipidaemia, which are all parts of the metabolic syndrome. In 2024, for non-cirrhotic MASH with mild to advanced… read more here.
Keywords: comprehensive review; review novel; mash comprehensive; mash ... See more keywords